glp 1 and osteoarthritis GLP-1RA 'might be disease-modifying' in knee with type 2 diabetes The Five-Year Incidence of Progression

Compounding is one of the oldest practices in pharmacy - before the rise of mass-manufactured pharmaceuticals in the twentieth century, virtually all medications were compounded by pharmacists

There have been pills specifically marketed as tanning pills'' for a while

NSAIDs combined with GLP-1 agonists carry increased risk of pancreatitis and kidney stress during rapid weight loss

GLP-1 drug penetration below 4% of eligible patients Top GLP-1 market: United States with 62.8% of global GLP-1 weight loss drug revenue Cardiovascular approval catalyst: Wegovy approved for MACE risk reduction following SELECT trial demonstrating 20% reduction in major adverse cardiovascular events Fastest-growing indication: Obstructive sleep apnea at 41.2% CAGR following Zepbound FDA approval November 2025 Market Overview: Why GLP-1 Weight Loss Drug Market Growth Is Accelerating The GLP-1 Weight Loss Drug Market is at an unprecedented commercial inflection point defined by three simultaneous demand accelerators

Racial and ethnic disparities and facility-level variation in GLP-1 RA prescription among US veterans with CKD

The benefits extend far beyond the gym